ASCO 2022: Neoadjuvant Pembrolizumab Shows Promise in Resectable Desmoplastic Melanoma
Findings suggest a role for single-agent PD-L1 blockade in the neoadjuvant setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.